Neuphoria Therapeutics (NEUP) Financials: Revenue & Earnings
NEUP$3.09-0.27 -8.04%
$16.72M
Market Cap
—
P/E
—
Forward P/E
—
Score
Neuphoria Therapeutics (NEUP) Financials: Revenue & Earnings
NEUP price $3.09 -0.27 -8.04%
- Ticker
- NEUP
- Price
- $3.09
- Change
- -0.27 -8.04%
- Market cap ?
- $16.72M
- Sector
- Healthcare
- Industry
- Biotechnology
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7…
Earnings and financials
Neuphoria Therapeutics Inc. (NEUP) trades at $3.09, with a market cap of $16.72M and a trailing P/E of n/a. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Insights · Dividends · Forecast · Financials · Learn